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Background: Progression of liver fibrosis is characterized by synthesis and degradation
of extracellular matrix (ECM). Matrix-metalloproteinases (MMP) cleave collagen fibers at
a specific site and thereby generate soluble fragments of ECM (neo-epitopes). The levels
of these neo-epitopes might reflect the stage of liver fibrosis and may allow monitoring of
anti-fibrotic therapies. Here we analyzed these neo-epitopes as read-out for a liver directed
therapy with statins.
Methods: Bile duct ligation (BDL) was performed on wild type rats, which received
atorvastatin (15mg/kg∗d) for 1 week starting at 1, 2, 3, 4 and 5 weeks after
BDL (T1–T5), while controls remained untreated. Hepatic fibrosis was analyzed by
immunohistochemistry and hepatic hydroxyproline content. TGFβ levels were measured
by RT-PCR. Proteolytic activity of MMP-2 was examined by zymography. Levels of
degradation MMP driven type I, III, IV and VI collagen degradation (C1M, C3M, C4M,
and C6M) and type III and IV collagen formation (PRO-C3 and P4NP7S) markers were
assessed by specific ELISAs in serum probes.
Results: Serum markers of ECM neo-epitopes reflected significantly the deposition of
ECM in the liver and were able to distinguish between early (T1–T3) and severe fibrosis
(T4–T5). Statin treatment resulted in reduction of neo-epitope markers, especially when
therapy was started in the stage of severe fibrosis (T4–T5). Furthermore, these markers
correlated with hepatic expression of profibrotic cytokines TGFβ1 and TGFβ2. Formation
markers of type III and IV collagen (PRO-C3 and P4NP7S) and degradation markers
C4M and C6M correlated significantly with hepatic MMP-2 activity in rats with severe
fibrosis.
Conclusion: Determination of ECM remodeling turnover markers in serum allowed a
distinction between mild and severe fibrosis. With respect to statin therapy, the markers
may serve as read-out for efficacy of anti-fibrotic treatment.
Keywords: fibrosis, statins, markers, antifibrotic, ECM (extracellular matrix), remodeling
INTRODUCTION
Progressive liver fibrosis is a consequence of chronic hepatic
inflammation from various causes (Friedman, 2003). The ulti-
mate result is cirrhosis and end-stage liver disease, which has a
huge impact on the patient’s morbidity and mortality as well as
medical and financial resources world-wide (Brundtland, 2002).
The key-process during progression of liver fibrosis is the synthe-
sis and deposition of extracellular matrix (ECM), which mainly
consists of different collagen types. The responsible cells for scar-
formation in the liver are hepatic myofibroblasts, mainly deriving
from hepatic stellate cells. These are activated and stimulated
by the ongoing inflammation in the liver which is associated
with formation of profibrotic cytokines including transform-
ing growth factor-β (TGFβ) (Friedman, 2001, 2008; Pinzani,
2002; Bataller and Brenner, 2005). However, it is important to
emphasize that fibrosis progression is dynamic and constitutes
both formation and degradation of ECM, which becomes imbal-
anced during liver disease (Gressner and Weiskirchen, 2006;
Friedman, 2008; Parola et al., 2008). During this remodeling
process endopeptidases such as matrix-metalloproteinase-2 and
-9 (MMP-2 and -9) are upregulated and are able to degrade
excessive ECM (Barascuk et al., 2010). Small ECM protein frag-
ments are released and may enter the circulation and may serve
as systemic biochemical markers of hepatic ECM remodeling.
The sites of degradation by specific MMPs are distinct and are
known as neo-epitopes. These neo-epitopes can be measured
using novel protein finger-print techniques (Karsdal et al., 2010,
2012).
Only few clinical trials have been conducted to test new
anti-fibrotic drugs in patients with liver diseases, partly because
reliable parameters for long-term monitoring of the therapeutic
effect are lacking. Liver biopsy, as a widely accepted technique,
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is invasive and shows problems of gaining representative sam-
ples as well as the inter-observer variation (Bedossa et al., 2003).
Transient elastography is non-invasive and a more and more
accepted tool to assess fibrosis. Nevertheless, this technique car-
ries restrictions related to cholestasis, obesity, severe inflamma-
tion and dialysis (Coco et al., 2007; Arena et al., 2008; Millonig
et al., 2008, 2010; Koch et al., 2011; Trabut et al., 2012). Therefore,
additional markers reflecting hepatic fibrotic activity and thera-
peutic effects of antifibrotic agents are needed.
Thus, the present study aims to validate novel serological
markers of ECM remodeling (ECMR) that reflect hepatic fibrotic
activity at different stages of fibrosis after bile-duct ligation in
rats (I), and to investigate whether they mirror the therapeu-
tic effect of HMG-CoA-reductase inhibitors (II) (Trebicka et al.,
2010; Klein et al., 2012).
MATERIALS AND METHODS
ANIMALS AND TREATMENT REGIMENS
Sprague-Dawley rats with an initial body weight of 180–200 g
were used. Twenty-four rats underwent BDL as previously
described (Trebicka et al., 2007, 2010; Klein et al., 2012). Twenty-
one rats underwent BDL and were additionally treated with a spe-
cific dosage of atorvastatin (Trebicka et al., 2007, 2010; Klein et al.,
2012) (15mg/kg body weight per day). This study was autho-
rized by the local committee for animal studies (Bezirksregierung
Köln, 50.203.2-BN22, 46/05). All rats received chow and water ad
libidum. Atorvastatin was administrated as described (Trebicka
et al., 2007, 2010; Klein et al., 2012). The rats were daily weighed
and pair-fed. The treatment regimens are shown in Figure 1.
Respective BDL rats received atorvastatin chow for 1 week start-
ing on distinct time points after BDL, 1 (T1), 2 (T2), 3 (T3), 4
(T4) or 5 (T5) weeks after BDL. BDL control rats were sacrificed
at the corresponding time points after BDL.
2 weeks
7 days 7days
3 weeks
2 weeks 7 days
4 weeks
3 weeks 7 days
5 weeks
4 weeks 7 days
6 weeks
5 weeks 7 days
T1
T2
T3
T4
T5
BDL
early fibrosis
severe fibrosis
BDL
BDL + atorvastatin
FIGURE 1 | Experimental design. Bile duct ligated (BDL) rats were used
with or without atorvastatin treatment for 1 week at different times after
BDL. T1 to T3 were pooled in group early fibrosis. T4–T5 were pooled in
group severe fibrosis. Each group with a minimum of n = 7.
TISSUE COLLECTION AND BIOCHEMICAL ANALYSIS
Animals were sacrificed after the described time points, blood was
withdrawn to measure biochemical parameters (ALT, AP, AST,
bilirubin, creatinine and γGT) and plasma samples were isolated
using standard methods. Liver samples were cut into fragments
and either snap-frozen in liquid nitrogen and stored at −80◦C
or preserved in formaldehyde as described previously (Trebicka
et al., 2007, 2008, 2010).
HEPATIC HYDROXYPROLINE CONTENT
Hepatic hydroxyproline was determined photometrically in liver
hydrolysates (Trebicka et al., 2007, 2010). Segments (200mg) of
snap-frozen livers were hydrolyzed in HCl (6N) at 110◦C for
16 h and filtered. Aliquots (50μl) from each sample were incu-
bated with chloramine T (2.5mM) for 5min and Ehrlich’s reagent
(410mM) for 30min at 60◦C. Absorption was measured three
times at 558 nm. For determination of hydroxyproline concen-
tration a standard curve for hydroxyproline was used. Results are
expressed as μg/g of wet liver tissue.
SIRIUS-RED STAINING, αSMA-IMMUNOHISTOCHEMISTRYAND
MORPHOMETRY
Liver specimens were fixed in 10% formalin. As described pre-
viously (Trebicka et al., 2007, 2010), paraffin-embedded sections
(2–3μm) were stained in 0.1% Sirius-red F3B in saturated picric
acid (Chroma, Münster, Germany) to detect collagen fibers.
For immunohistochemical staining of α-smooth muscle actin
(αSMA) sections were incubated with an mouse-anti-αSMA anti-
body (clone 1A4, Sigma-Aldrich, St. Louis, USA) diluted 1:600 in
Tris-buffered saline for 60min. A biotinylated rabbit-anti-mouse
antibody, absorbed wit rat serum (Dako, Glostrup, Denmark),
was used as secondary antibody and applied subsequently diluted
1:200 for 45min. Streptravidin-conjugated alkaline phosphatase
(1:200, 45min; Dako) was then attached to the complex. Sections
were finally developed with new fuchsin-naphtol AS-BI (Sigma-
Aldrich) and counterstained with hematoxyline.
Stereomicroscopic analysis was performed as described pre-
viously (Trebicka et al., 2007, 2010). On sections with a surface
of 1 cm2 five hundred points were counted on a magnification
of 400x. On Sirius-red staining test points were classified as
connective tissue (positive staining), as well as hepatocytes, bile
ducts or other structures (not stained). αSMA positive cells were
counted on αSMA-immunohistological sections and character-
ized by their location as sinusoidal, periductular, portal/septal and
others (e.g., vascular smooth muscle cells). The volume fraction
of each structure was calculated as percentage of points overlaying
the structure in relation to the total number of counted points.
QUANTITATIVE RT-PCR
RNA was isolated from liver segments of 30mg using the RNeasy
kit (Qiagen, Basel, Switzerland) with DNase treatment (Promega,
Wallisellen, Switzerland) followed by reverse transcription with
M-MLV reverse transcriptase (Invitrogen, Basel, Switzerland)
according to the manufacturers’ instructions. Quantitative PCR
was carried out on the ABI 7700 sequence detector (Applied
Biosystems, Rotkreuz, Switzerland) with previously described
sequences and accession numbers (Trebicka et al., 2010). Gene
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expression values were calculated based onCt method (Trebicka
et al., 2007, 2010; Klein et al., 2012) and normalized to expres-
sion of GAPDH. Results were calculated as 2−Ct and express
the x-fold increase of gene expression compared to sham operated
rats.
MMP-2 ZYMOGRAPHY
Proteolytic activity of tissue homogenates was examined by gela-
tine zymography as previously published (Trebicka et al., 2010).
The supernatants of liver homogenates (20μg of protein) were
subjected to 10% SDS-PAGE using gels containing 0.3% gelatine.
Proteolytic bands of 62 and 65 kDa, corresponding to the active
and latent form of MMP-2 respectively were quantified by densit-
ometry using AIDA software (Raytest, Urdorf, Switzerland).
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Serological markers for MMP degradation of ECM proteins C1M
(type I collagen), C3M (type III collagen), C4M (type IV colla-
gen), C6M (type VI collagen), and formation markers PRO-C3
(type III collagen), P4NP 7S (type IV collagen) were assessed
according to protocol in plasma of each rat using technical robust
enzyme linked immunosorbent assays as described previously
(see Table 1) (Barascuk et al., 2010; Veidal et al., 2011a,b; Leeming
et al., 2011, 2012; Nielsen et al., 2013). Each marker was stratified
according to time of BDL and atorvastatin treatment. The serum
was obtained from previously analyzed animals (Trebicka et al.,
2010).
STATISTICAL ANALYSIS
Data are presented as mean ± standard error of the mean (SEM).
Mann–Whitney-U-test or Wilcoxon was used for comparison
between groups as appropriate. For computation of the correla-
tions SPSS (Chicago, USA) was used. Two sided p-values <0.05
were considered statistically significant.
RESULTS
SERUM LEVELS OF ECM REMODELINGMARKERSMIRRORED THE
QUANTITY OF HEPATIC FIBROSIS IN BDL RATS
The serum levels of all ECMR markers of degradation and for-
mation of ECM-proteins were negatively correlated with the
hepatocyte mass (Table 2). This correlation was observed in all
rats, as well as in severe fibrosis regardless of treatment (Table 2).
Of note there was no correlation of any ECMR marker with cre-
atinine and therefore these markers were not influenced by renal
function (data not shown).
The deposition of total collagen, quantified by Sirius-red
staining and hydroxyproline content in untreated rats correlated
with all markers highly significant with ECM amount (Table 2,
Figure 2).
Furthermore, the levels of the ECMR markers in all ani-
mals with different fibrosis severity (T1–T5), as well as in severe
fibrosis (T4, T5) correlated with the hepatic collagen amount
regardless of atorvastatin treatment (Table 2). However, these
correlations were not as strong as in untreated animals, sug-
gesting that atorvastatin treatment had an effect on the lev-
els of these neo-epitope markers differentially to the hepatic
collagen quantity determined by staining and hydroxyproline
content.
The levels of collagen formation assessed serologically (PRO-
C3 and P4NP7S), as well as of the collagen degradation markers
C3M and C6M were significantly lower in early fibrosis (T1–T3)
compared to late stages of fibrosis (T4, T5) independent of statin
treatment as shown in Table 3.
Summarizing these data, the markers reflect ECM deposition
in the liver and discriminate between early and severe fibrosis.
SERUM LEVELS OF ECM REMODELINGMARKERS ANALYSED ON
WEEKLY BASIS AFTER BDL
We have previously shown that 1 week of atorvastatin treat-
ment prevented ECM deposition in the early stages of fibro-
sis (T1–T3), but did not change the amount of ECM signif-
icantly in severe fibrosis (Trebicka et al., 2010). Interestingly,
the ECRM markers provided a slightly different picture. When
statin treatment was started 1 week after BDL (T2) the degra-
dation markers for type III and IV collagen increased in serum
of these animals (Figures 3B,C), whereas in the early fibrosis
(T1) the levels of the degradation marker for collagen type VI
(C6M) decreased significantly (Figure 3D). The levels of degra-
dation marker type I collagen and formation markers for type
III and IV were not significantly influenced in early fibrosis
(Figures 3A,E,F).
In severe fibrosis (T4, T5), the levels of all neo-epitopes for
degradation and formation show the same trend, since they are
decreased by atorvastatin treatment (Figure 3). Especially in T5,
we observed a statistical significant decrease in serum levels of
C4M, C6M, PRO-C3, P4NP7S (Figures 3C–F). In the T5 group
we have previously observed an effect of atorvastatin on the
turnover of activated HSC and secretory activity ofmyofibroblasts
due to induction of senescence in these cells (Trebicka et al., 2010;
Klein et al., 2012).
Table 1 | Overview of used degradation and formation markers of ECM.
Assay Target Antibody Detection Intra-assay Inter-assay References
name type range (ng/mL) variation (%) variation (%)
C1M MMP-2/9/13 degraded type I collagen Monoclonal 0.83–500 10.1 6.7 Leeming et al., 2011
C3M MMP-9 degraded type III collagen Monoclonal 0.9–50 4.7 6.5 Barascuk et al., 2010
C4M MMP-2/9 degraded type IV collagen Monoclonal 0.6–100 4.8 12.1 Veidal et al., 2011a
C6M MMP-2/9 degraded type VI collagen Monoclonal 0.3–250 4.1 10.1 Veidal et al., 2011b
PRO-C3 N-terminal propeptide of type III collagen Monoclonal 0.9–200 4.1 11.0 Nielsen et al., 2013
P4NP 7S 7S domain of type IV collagen Monoclonal 7.9–500 9.7 11.7 Leeming et al., 2012
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Table 2 | Correlations of hepatic histology and function with ECM markers.
Biomarker
C1M C3M C4M C6M PRO-C3 P4NP 7S
r r r r r r
Hepatocytes (staining) All animals −0.393** −0.318* −0.346* −0.549** −0.424** −0.529**
Untreated animals −0.563** −0.391p=0.065 −0.538** −0.553** −0.373p=0.079 −0.479*
Atorvastatin treated animals −0.548* −0.618** −0.551* −0.670** −0.565* −0.682**
ECM (staining) All animals 0.386* n.s. 0.355* 0.586** 0.511** 0.566**
Untreated animals 0.577** 0.451* 0.583** 0.664** 0.590** 0.628**
Atorvastatin treated animals 0.424p=0.090 0.518* n.s. 0.560* 0.540* 0.550*
Hepatic hydroxyproline
content
All animals n.s. n.s. n.s. 0.445** 0.403* 0.464**
Untreated animals 0.699** 0.626** 0.779** 0.818** 0.683** 0.681**
Atorvastatin treated animals 0.631p=0.050 n.s. 0.716* 0.662* 0.596p=0.069 0.532p=0.114
Significance of correlations were defined by non-parametric testing (n=minimum 7/group) and p<0.05 was considered significant. Data are presented as Pearson
correlation coefficient (r) of ECM or hepatic hydroxyproline content with ECMR markers (C1M, C3M, C4M, C6M, PRO-C3 and P4NP7S). Asterisks indicate statistical
significant correlations. (*p < 0.05, **p < 0.01, n.s, not significant).
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FIGURE 2 | Correlation of hepatic hydroxyproline content with ECM markers. Correlations with degradation markers shown in black, correlations with
formation markers shown in gray.
LEVELS OF ECM REMODELINGMARKERS IN SERUM OF BDL RATS
TREATED FOR 1 WEEKWITH ATORVASTATIN IN EARLY AND SEVERE
FIBROSIS
The effects of atorvastatin could be divided into basically two dif-
ferent types: on the one side the early effect on the prevention of
activation of HSC (early stages of fibrosis) and on other side the
blunting of activity and induction of senescence inmyofibroblasts
(severe stages of fibrosis). We, therefore, cumulatively analyzed
the levels of these marker in early and severe fibrosis (Trebicka
et al., 2010; Klein et al., 2012).
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Table 3 | Levels of ECM markers in blood.
Group C1M (ng/ml) C3M (ng/ml) C4M (ng/ml) C6M (ng/ml) PRO-C3 (ng/ml) P4NP7S (ng/ml)
T1 95.01 ± 5.16 34.02± 2.33 100.17 ± 4.37 12.32 ± 0.60 36.51 ± 3.50 535.64± 55.29
T2 113.95± 8.72 37.73± 2.63 115.84± 9.77 18.12± 1.37b 50.86 ± 2.85b 669.76± 32.23
T3 114.40± 7.64 40.15± 5.26 119.41± 8.79 15.30 ± 1.20 43.01 ± 4.86 592.13± 78.00
early fibrosis 108.01 ± 4.62 37.32± 2.12 111.95± 4.96 15.35 ± 0.79 43.73 ± 2.45 601.69± 34.46
T4 125.25± 16.76 46.97± 8.18 127.50± 17.53 21.29 ± 3.21a 56.03 ± 9.85 932.55± 131.06a
T5 117.12± 8.73 46.09± 4.56a 118.77± 10.53 21.52 ± 2.42b 62.29 ± 9.15a 989.46± 140.45a
Severe fibrosis 120.47± 8.66 46.45± 4.31c 122.37± 9.57 21.43 ± 1.94d 59.72 ± 6.78c 966.02± 98.92d
Each point in time consist of BDL rats with and without atorvastatin treatment. Points in time T1–T3 are pooled in group early fibrosis. Points in time T4–T5 are
pooled in group severe fibrosis. Data are means ± standard errors for all points of time. Letters a to d indicate statistical significance. (a, p < 0.05 vs. T1; b, p < 0.01
vs. T1; c, p < 0.05 vs. early fibrosis, d, p < 0.01 vs. early fibrosis).
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FIGURE 3 | Levels of ECMmarkers in blood with (+AT) or without (–AT)
atorvastatin treatment. BDL rat liver fibrosis model with atorvastatin
intervention 1 (T1), 2 (T2), 3 (T3) and 5 (T5) weeks post BDL surgery.
Plasma levels of C1M, C3M, C4M, C6M, PRO-C3, and P4NP 7S levels are
shown as mean levels ± standard errors for all time points. Asterisks
indicate statistical significance as indicated by bars. (∗p < 0.05, ∗∗p < 0.01).
Analyzed together atorvastatin treatment for 1 week did not
changed significantly the levels of ECM degradation or formation
in early fibrosis (1, 2, or 3 weeks after BDL) (Figures 4A,C–F).
The only exception was the degradation neo-epitope for col-
lagen type III, which increased after atorvastatin (Figure 4B).
In a previous study these early stages showed significant lower
hydroxyproline content and Sirius-red staining areas after ator-
vastatin treatment (Trebicka et al., 2010). By contrast, the serum
levels of neo-epitopes for degradation and formation of ECM
decreased after 1 week of atorvastatin treatment at late stages
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FIGURE 4 | Comparison of early and severe fibrosis for all ECM markers
in atorvastatin treated or untreated animals. Different points of time
were pooled into groups early fibrosis (T1–T3) and group servere fibrosis
(T4 and T5) and separated by statin treated (+AT) and untreated (−AT)
animals. Asterisks indicate statistical significance as indicated by bars.
(∗p < 0.05, ∗∗p < 0.01).
of fibrosis (after 4 and 5 weeks of BDL) (Figure 4). These data
suggest that these novel ECM degradation and formation mark-
ers might reflect the amount of fibrosis, as well as the effect of
an anti-fibrotic treatment before the amount of ECM changes
notably in the liver.
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SERUM LEVELS OF NEO-EPITOPES OF ECM CORRELATEDWITH
HEPATIC EXPRESSION OF PROFIBROTIC CYTOKINES
Hepatic mRNA levels of TGFβ1 and TGFβ2 in BDL rats were
highly correlated with the serum levels of degradation markers for
type I and IV collagen, as well as formation markers for type III
and IV collagen, regardless of treatment (Table 4, Figures 5A,B).
Interestingly, the hepatic mRNA levels of TGFβ1 and TGFβ2
showed strong correlation with almost all these neo-epitopes of
ECM, when the early or the severe fibrosis group was observed
separately. Similarly, strong correlations of TGFβ1 and TGFβ2
hepatic mRNA levels were observed with these markers when the
treated and untreated animals were analyzed separately (Table 4;
Figures 5A,B). Of note, atorvastatin treatment decreased the hep-
atic levels of these cytokines in severe fibrosis stages of BDL
animals as shown previously (Trebicka et al., 2010), similarly to
the now described levels of neo-epitopes (Figure 4).
THE SERUM LEVELS OF ECM REMODELINGMARKERS REFLECT
HEPATIC ECM TURNOVER IN BDL INDUCED FIBROSIS
The serum levels of the degradation marker for type IV and VI
collagen, as well as formation markers for type III and IV col-
lagen correlated strongly and significantly with hepatic MMP-2
levels measured by zymography in the rats with severe fibrosis
(Figures 5C–F). Active MMP-2 and its activity calculated as the
ratio of active to latent MMP-2 correlated strongly with all degra-
dation and formation markers in severe fibrosis, pointing out
that ECM markers display the turnover of ECM in liver disease
(Table 5, Figures 5C–F).
DISCUSSION
The present study demonstrates that novel serum markers of
ECMR reflect the dynamic process of fibrosis and may thereby
used to assess effects of antifibrotic therapies.
Liver fibrosis is usually a slow progressing disease and it may
take decades to develop first symptoms and complications. In
the end-stage of liver disease, liver cirrhosis, the patients show
many severe complications and may decompensate rapidly. At
these stages the only therapeutic options are liver transplantation
and/or treatment of the complications. Therefore, attenuation or
even interruption of fibrosis progression is an important thera-
peutic goal. Therapy varies dependent on etiology of disease and
during therapy—nomatter which—it would be most desirable to
monitor its effect on the fibrotic process.
The tissue ECMR was assessed using newly developed ELISAs,
that utilizemonoclonal antibodies raised against specific degrada-
tion fragments unique for ECM proteins that are involved in the
development of liver fibrosis and are remodeled by disease rele-
vant proteases. Theymay carry unique disease “fingerprints,” why
this approach is coined Protein Fingerprint Technology (Karsdal
et al., 2009, 2012; Barascuk et al., 2010; Vassiliadis et al., 2011;
Veidal et al., 2011a,b; Leeming et al., 2012, 2013). These markers
have been validated in different models and severities of fibro-
sis in previous studies and compared to control non-fibrotic rats
(Karsdal et al., 2009, 2012; Barascuk et al., 2010; Vassiliadis et al.,
2011; Veidal et al., 2011a,b; Leeming et al., 2012, 2013).
In our BDL model we observed higher levels of these markers
in early fibrosis, compared to severe fibrosis (Table 3). Moreover
the levels of ECMR markers correlated very strongly with the
amount of ECM, especially in the untreated BDL group. In
these untreated animals, the fibrosis progression was assessed on
weekly basis after BDL, as previously described (Trebicka et al.,
2010). This on the one hand confirms previous findings and on
the other hand validates our present findings in this rat model
(Table 2).
The mechanisms of progressing fibrosis have been widely
investigated in animal models, and many strategies have been
published to blunt or attenuate fibrosis. However, in humans only
a few trials have tested anti-fibrotic agents. One important rea-
son for this is that animals can be treated concomitantly with
initiation of hepatic injury, which makes it easier to assess the
Table 4 | Correlations of mRNA levels from profibrotic cytokines with ECM markers.
Biomarker
C1M C4M C6M PRO-C3 P4NP 7S
r r r r r
All animals 0.382** 0.485** 0.506** 0.583** 0.505**
TGFβ1 mRNA (x-fold) Untreated animals 0.359p =0.085 0.541** 0.420* 0.413* 0.380p =0.067
Atorvastatin treated animals 0.536* 0.379p =0.090 0.372p =0.097 0.687** 0.687**
Early fibrosis n.s. n.s. 0.384* 0.576** n.s.
Severe fibrosis 0.505* 0.723** 0.526* 0.560* 0.604*
TGFβ2 mRNA (x-fold) All animals 0.345* 0.353* 0.496** 0.488** 0.512**
Atorvastatin treated animals 0.515* n.s. 0.454* 0.526* 0.646**
Early fibrosis 0.304p =0.115 n.s. 0.427* 0.425* 0.332p =0.085
Severe fibrosis n.s. 0.556* 0.508* 0.508* 0.622
Significance of correlations were defined by non-parametric testing (n = minimum 7/group) and p < 0.05 was considered significant. Data are presented as Pearson
correlation coefficient (r) of mRNA levels of profibrotic cytokines (TGFβ1 and TGFβ2) with respective ECMR markers (C1M, C4M, C6M, PRO-C3 and P4NP 7S).
Asterisks indicate statistical significant correlations. (*p < 0.05, **p < 0.01, n.s, not significant).
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FIGURE 5 | (A,B) Correlation of formation markers with profibrotic cytokine
TGFβ1 in atorvastatin treated or untreated animals. Correlations with
untreated animals shown in black, correlations with atorvastatin treated
animals shown in gray. (C–F) Correlation of ECM turnover with ECM markers
in severe fibrosis. Correlations with active MMP-2 shown in black,
correlations of ratio active/latent shown in gray.
Table 5 | Correlation of ECM turnover with ECM markers.
Biomarker
C4M C6M PRO-C3 P4NP 7S
r r r r
MMP-2 lat severe fibrosis 0.576p=0.081 0.715* 0.840** 0.835**
MMP-2 akt severe fibrosis 0.653* 0.756* 0.892** 0.844**
MMP-2 akt/lat severe fibrosis 0.692* 0.657* 0.837** 0.777**
Significance of correlations were defined by non-parametric testing (n = minimum 7/group) and p < 0.05 was considered significant. Data are presented as Pearson
correlation coefficient (r) of MMP-2 (latent, active and ratio of active to lantent) with respective ECM markers (C4M, C6M, PRO-C3 and P4NP7S). Asterisks indicate
statistical significant correlations. (*p < 0.05, **p < 0.01, n.s, not significant).
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effect in the amount of fibrosis accumulated. In early fibrosis, it
is easy to assess differences in the amount of fibrosis, as shown
in our animal model (Trebicka et al., 2010). In severe fibrosis,
the total amount of fibrosis is inadequate for the assessment of
the treatment success. Atorvastatin prevents the accumulation of
ECM, when it is administered in early phases of fibrosis in a
BDL model of rats (Trebicka et al., 2010). Indeed, atorvastatin
inhibited the activation of hepatic stellate cells in vitro the main
producers of ECM in early phases of fibrosis (Klein et al., 2012).
The clinical situation is different; the patients come for treat-
ment when fibrosis is severe and clinically evident. In these
severe fibrosis the total amount of ECM does not change
rapidly, therefore a long-term follow-up are needed to assess
treatment effects. In our model, we mimicked this situation.
In severe fibrosis (4 and 5 weeks after BDL) the rats were
treated for 1 week with atorvastatin. The amount of ECM
did not change significantly, but we observed a significant
effect on the remodeling of ECM, since MMP-2 activity was
blunted, the expression of profibrotic cytokines TGFβ1 and
TGFβ2 were decreased (Trebicka et al., 2010; Klein et al., 2012).
The serum levels of ECMR markers correlated strongly with
TGFβ levels, as well as with active MMP-2 and MMP-2-activity,
assessed as the ratio of active to latent MMP-2 (Tables 4, 5,
Figures 5C–F). This demonstrates that the levels of these mark-
ers mirror early changes in the fibrosis progression, even before
the ECM amount is changed. This is the first evidence that
serum levels of these ECMR markers as read-out for anti-
fibrotic treatment. The comparison of the accuracy of these
markers with other serological fibrosis markers and the inves-
tigation in other models of fibrosis should be topic of future
studies.
In severe fibrosis statin treatment decreased the turnover of
activated hepatic stellate cells (Trebicka et al., 2010), due to
the induction of senescence in these profibrogenic cells (Klein
et al., 2012). In the present study, we showed that these profi-
brogenic cells produce less collagen (formation markers) and the
turnover of ECM is reduced as well (as shown by reduced degra-
dation markers), which led to the observation that in the severe
fibrosis statin treatment for 1 week did not decrease the static
amount of total collagen in the liver assessed by hydroxypro-
line content and Sirius-red-staining (Trebicka et al., 2010). In
conclusion, these markers reflect the release of ECM-fragments
into circulation and probably mirror dynamics of fibrogenesis.
Thus, they are related to disease activity and may potentially also
carry prognostic information. Therefore, they should be tested
for monitoring the effect of antifibrotic treatment in human
diseases.
ACKNOWLEDGMENTS
The study was supported by grants from the Deutsche
Forschungsgemeinschaft (SFB TRR57 project 18), the Bonfor-
Stiftung (O-107.0084 and O-107.0103) and from J. & W. Hector-
Foundation. The biomarker assessments were supported by the
Danish science foundation (“Den Danske Forskningsfond”). The
authors thank G. Hack and S. Bellinghausen for excellent techni-
cal assistance.
REFERENCES
Arena, U., Vizzutti, F., Corti, G., Ambu,
S., Stasi, C., Bresci, S., et al. (2008).
Acute viral hepatitis increases liver
stiffness values measured by tran-
sient elastography. Hepatology 47,
380–384. doi: 10.1002/hep.22007
Barascuk, N., Veidal, S. S., Larsen,
L., Larsen, D. V., Larsen, M. R.,
Wang, J., et al. (2010). A novel
assay for extracellular matrix
remodeling associated with
liver fibrosis: an enzyme-linked
immunosorbent assay (ELISA) for
MMP-9 proteolytically revealed
neo-epitope of type III collagen.
Clin. Biochem. 43, 899–904. doi:
10.1016/j.clinbiochem.2010.03.012
Bataller, R., and Brenner, D. A. (2005).
Liver fibrosis. J. Clin. Invest. 115,
209–218.
Bedossa, P., Dargere, D., and Paradis,
V. (2003). Sampling variability of
liver fibrosis in chronic hepatitis C.
Hepatology 38, 1449–1457.
Brundtland, G. H. (2002). From
the World Health Organization.
Reducing risks to health, promoting
healthy life. JAMA 288, 1974. doi:
10.1001/jama.288.16.1974
Coco, B., Olivieri, F., Maina, A.
M., Ciccorossi, P., Sacco, R.,
Colombatto, P., et al. (2007).
Transient elastography: a new
surrogate marker of liver fibrosis
influenced by major changes of
transaminases. J. Viral Hepat. 14,
360–369. doi: 10.1111/j.1365-2893.
2006.00811.x
Friedman, S. L. (Ed.). (2001). “The
hepatic stellate cell,” in Semin Liver
Dis. (New York, NY: Thieme),
307–452.
Friedman, S. L. (2003). Liver fibrosis—
from bench to bedside. J. Hepatol.
38(Suppl. 1), S38–S53. doi:
10.1016/S0168-8278(02)00429-4
Friedman, S. L. (2008). Mechanisms
of hepatic fibrogenesis.
Gastroenterology 134, 1655–1669.
doi: 10.1053/j.gastro.2008.03.003
Gressner, A. M., and Weiskirchen, R.
(2006). Modern pathogenetic con-
cepts of liver fibrosis suggest stellate
cells and TGF-beta as major players
and therapeutic targets. J. Cell. Mol.
Med. 10, 76–99. doi: 10.1111/j.1582-
4934.2006.tb00292.x
Karsdal, M. A., Henriksen, K.,
Leeming, D. J., Mitchell, P., Duffin,
K., Barascuk, N., et al. (2009).
Biochemical markers and the FDA
Critical Path: how biomarkers may
contribute to the understanding
of pathophysiology and provide
unique and necessary tools for
drug development. Biomarkers. 14,
181–202. doi: 10.1080/135475009
02777608
Karsdal,M. A., Henriksen, K., Leeming,
D. J., Woodworth, T., Vassiliadis,
E., and Bay-Jensen, A. C. (2010).
Novel combinations of Post-
Translational Modification (PTM)
neo-epitopes provide tissue-specific
biochemical markers–are they
the cause or the consequence
of the disease? Clin. Biochem.
43, 793–804. doi: 10.1016/j.clin
biochem.2010.03.015
Karsdal, M. A., Nielsen, M. J., Sand,
J. M., Henriksen, K., Genovese, F.,
Bay-Jensen, A. C., et al. (2012).
Extracellular matrix remodeling:
the common denominator in
connective tissue diseases possi-
bilities for evaluation and current
understanding of the matrix as
more than a passive architecture,
but a key player in tissue failure.
Assay Drug Dev. Technol. 11, 70–92.
doi: 10.1089/adt.2012.474
Klein, S., Klosel, J., Schierwagen, R.,
Korner, C., Granzow, M., Huss,
S., et al. (2012). Atorvastatin
inhibits proliferation and apop-
tosis, but induces senescence in
hepatic myofibroblasts and thereby
attenuates hepatic fibrosis in rats.
Lab. Invest. 92, 1440–1450. doi:
10.1038/labinvest.2012.106
Koch, A., Horn, A., Duckers, H.,
Yagmur, E., Sanson, E., Bruensing,
J., et al. (2011). Increased liver stiff-
ness denotes hepatic dysfunction
and mortality risk in critically ill
non-cirrhotic patients at a medical
ICU. Crit. Care 15, R266.
Leeming, D., He, Y., Veidal, S., Nguyen,
Q., Larsen, D., Koizumi, M.,
et al. (2011). A novel marker
for assessment of liver matrix
remodeling: an enzyme-linked
immunosorbent assay (ELISA)
detecting a MMP generated type
I collagen neo-epitope (C1M).
Biomarkers 16, 616–628. doi:
10.3109/1354750X.2011.620628
Leeming, D. J., Byrjalsen, I., Jiménez.,
Christiansen, C., and Karsdal, M.
A. (2013). Protein fingerprint-
ing of the extracellular matrix
remodelling in a rat model of liver
fibrosis-a serological evaluation.
Liver Int. 33, 439–447. doi: 10.1111/
liv.12044
Leeming, D. J., Nielsen, M. J., Dai, Y.,
Veidal, S. S., Vassiliadis, E., Zhang,
C., et al. (2012). An Enzyme-
linked Immunosorbent Serum
Assay (ELISA) specific for the
7S domain of Collagen Type IV
Frontiers in Physiology | Gastrointestinal Sciences July 2013 | Volume 4 | Article 195 | 8
Schierwagen et al. ECM markers reflect antifibrotic therapy
(PIVNP 7S) -a marker related to
the extracellular matrix remod-
eling during liver fibrogenesis.
Hepatol. Res. 42, 482–493. doi:
10.1111/j.1872-034X.2011.00946.x
Millonig, G., Friedrich, S., Adolf, S.,
Fonouni, H., Golriz, M., Mehrabi,
A., et al. (2010). Liver stiffness
is directly influenced by central
venous pressure. J. Hepatol. 52,
206–210.
Millonig, G., Reimann, F. M., Friedrich,
S., Fonouni, H., Mehrabi, A.,
Buchler, M. W., et al. (2008).
Extrahepatic cholestasis increases
liver stiffness (FibroScan) irre-
spective of fibrosis. Hepatology 48,
1718–1723. doi: 10.1002/hep.22577
Nielsen, M. J., Nedergaard, A. F., Sun,
S., Veidal, S. S., larsen, L., Zheng,
Q., et al. (2013). The neo-epitope
specific PRO-C3 ELISA measures
true formation of type III colla-
gen associated with liver and mus-
cle parameters. Am. J. Trans. Res. 5,
303–315.
Parola, M., Marra, F., and Pinzani, M.
(2008).Myofibroblast - like cells and
liver fibrogenesis: Emerging con-
cepts in a rapidly moving sce-
nario. Mol. Aspects 29, 58–66. doi:
10.1016/j.mam.2007.09.002
Pinzani, M. (2002). PDGF and signal
transduction in hepatic stellate cells.
Front. Biosci. 7, d1720–d1726.
Trabut, J. B., Thepot, V., Nalpas,
B., Lavielle, B., Cosconea, S.,
Corouge, M., et al. (2012). Rapid
decline of liver stiffness follow-
ing alcohol withdrawal in heavy
drinkers. Alcohol. Clin. Exp. Res.
36, 1407–1411. doi: 10.1111/j.1530-
0277.2012.01737.x
Trebicka, J., Hennenberg, M., Laleman,
W., Shelest, N., Biecker, E., Schepke,
M., et al. (2007). Atorvastatin lowers
portal pressure in cirrhotic rats by
inhibition of RhoA/Rho-kinase and
activation of endothelial nitric oxide
synthase. Hepatology 46, 242–253.
doi: 10.1002/hep.21673
Trebicka, J., Hennenberg, M.,
Odenthal, M., Shir, K., Klein,
S., Granzow, M., et al. (2010).
Atorvastatin attenuates hepatic
fibrosis in rats after bile duct ligation
via decreased turnover of hepatic
stellate cells. J. Hepatol. 53, 702–712.
doi: 10.1016/j.jhep.2010.04.025
Trebicka, J., Leifeld, L., Hennenberg,
M., Biecker, E., Eckhardt,
A., Fischer, N., et al. (2008).
Hemodynamic effects of urotensin
II and its specific receptor antag-
onist palosuran in cirrhotic rats.
Hepatology 47, 1264–1276. doi:
10.1002/hep.22170
Vassiliadis, E., Larsen, D. V., Clausen,
R. E., Veidal, S. S., Barascuk,
N., Larsen, L., et al. (2011).
Measurement of CO3-610, a
potential liver biomarker derived
from matrix metalloproteinase-9
degradation of collagen type iii, in
a rat model of reversible carbon-
tetrachloride-induced fibrosis.
Biomark Insights 6, 49–58. doi:
10.4137/BMI.S6347
Veidal, S. S., Karsdal, M. A., Nawrocki,
A., Larsen, M. R., Dai, Y., Zheng,
Q., et al. (2011a). Assessment of
proteolytic degradation of the base-
ment membrane: a fragment of
type IV collagen as a biochemical
marker for liver fibrosis. Fibrogenesis
Tissue Repair 4:22. doi: 10.1186/
1755-1536-4-22
Veidal, S. S., Karsdal, M. A., Vassiliadis,
E., Nawrocki, A., Larsen, M. R.,
Nguyen, Q. H., et al. (2011b). MMP
mediated degradation of type VI
collagen is highly associated with
liver fibrosis–identification and
validation of a novel biochemical
marker assay. PLoS ONE 6:e24753.
doi: 10.1371/journal.pone.0024753
Conflict of Interest Statement:
Diana J. Leeming, Morten A. Karsdal,
and Mette J. Nielsen are employees
of Nordic Bioscience, a company
engaged in the development of
biochemical markers. Morten A.
Karsdal is stockholder of Nordic
Bioscience. The other authors declare
that the research was conducted in
the absence of any commercial or
financial relationships that could be
construed as a potential conflict of
interest.
Received: 29 May 2013; paper pending
published: 25 June 2013; accepted: 08
July 2013; published online: 30 July 2013.
Citation: Schierwagen R, Leeming DJ,
Klein S, Granzow M, Nielsen MJ,
Sauerbruch T, Krag A, Karlsdal MA and
Trebicka J (2013) Serum markers of the
extracellular matrix remodeling reflect
antifibrotic therapy in bile-duct ligated
rats. Front. Physiol. 4:195. doi: 10.3389/
fphys.2013.00195
This article was submitted to Frontiers in
Gastrointestinal Sciences, a specialty of
Frontiers in Physiology.
Copyright © 2013 Schierwagen,
Leeming, Klein, Granzow, Nielsen,
Sauerbruch, Krag, Karlsdal and
Trebicka. This is an open-access
article distributed under the terms of
the Creative Commons Attribution
License (CC BY). The use, distribution
or reproduction in other forums is per-
mitted, provided the original author(s)
or licensor are credited and that the
original publication in this journal
is cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.
www.frontiersin.org July 2013 | Volume 4 | Article 195 | 9
